Ibritumomab tiuxetan (90y)

Zevalin

3.2 MG / 2 ML Kit, SolutionCanadaAuthorisedAuthorised 12 Sept 2018

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

ZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSIONSpain · 1,6 mg · equipo de reactivos para preparación radiofarmacéutica · Ceft Biopharma S.R.O.Same brand
ZevalinEuropean Union · Ceft Biopharma s.r.o.Same brand
ZevalinCroatiaSame brand
ZevalinItaly · Kit per preparazione radiofarmaceutica · Ceft Biopharma S.R.O.Same brand
ZevalinUnited States · 3.2MG/2ML · injectable · Spectrum PharmsSame brand

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ibritumomab tiuxetan (90y)

Zevalin

3.2 MG / 2 ML Kit, SolutionCanadaAuthorisedAuthorised 12 Sept 2018

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entry

Health Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ibritumomab tiuxetan (90y)
Strength: 3.2 MG / 2 ML
Dosage form: Kit, Solution
Route: Intravenous
Register: Canada (Health Canada)
Status: Authorised
Status in the register: Approved
Authorised: 12 Sept 2018
Registration: DIN 02328674
Marketing authorisation holder: Auro Pharma INC
ATC code: V10XX02
Group: Various
Supply: SCHEDULE C